Myovant Sciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Myovant Sciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 12 Dec 2022 | Lorem |
| Myovant’s Phase III relugolix trial CV event reduction trend inconclusive; although approvable, castrate-sensitive prostate cancer drug switch a high hurdle, experts say | 11 Jun 2020 | Reynald Castaneda |
| Myovant’s lack of relugolix dosing options may hurt its usage in endometriosis-related pain; once-daily schedule helpful, experts say | 25 Nov 2019 | Manasi Vaidya |
| AbbVie’s Orilissa, Myovant’s relugolix both expected to face similar payer scrutiny in uterine fibroids as the former has in endometriosis, experts say | 02 Jul 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer